ProQR Therapeutics (PRQR) Accounts Payables (2013 - 2026)

ProQR Therapeutics (PRQR) has reported Accounts Payables for 14 consecutive years, with $215073.4 the latest figure, recorded in Q1 2026.

• Quarterly Accounts Payables fell 54.35% year-over-year to $215073.4 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $215073.4 (down 54.35% YoY) and the FY2025 annual result came in at $339110.4, up 1762.5% from the prior year.
• Accounts Payables fell to $215073.4 in Q1 2026 per PRQR's latest filing, from $339110.4 in the prior quarter.
• Over the last five years, Accounts Payables for PRQR reached as high as $1.8 million in Q4 2023 and fell as low as $18207.3 in Q4 2024.
• A 5-year average of $492734.2 and a median of $347076.1 in 2025 frame the typical range for Accounts Payables.
• Annual changes were most pronounced in 2022 — Accounts Payables surged 299536.36% — and 2024, when it tumbled 98.96%.
• Year by year, Accounts Payables stood at $446078.1 in 2022, then surged by 293.11% to $1.8 million in 2023, then slumped by 98.96% to $18207.3 in 2024, then soared by 1762.5% to $339110.4 in 2025, then plunged by 36.58% to $215073.4 in 2026.
• According to Business Quant data, Accounts Payables over the past three periods registered $215073.4, $339110.4, and $347076.1 for Q1 2026, Q4 2025, and Q3 2025 respectively.